BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22569213)

  • 21. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.
    Oh S; Shin S; Janknecht R
    Biochim Biophys Acta; 2012 Aug; 1826(1):1-12. PubMed ID: 22425584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
    Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ETS rearrangements and prostate cancer initiation.
    Carver BS; Tran J; Chen Z; Carracedo-Perez A; Alimonti A; Nardella C; Gopalan A; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
    Nature; 2009 Feb; 457(7231):E1; discussion E2-3. PubMed ID: 19212347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
    Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
    Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
    Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
    Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
    Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
    Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
    Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ETS gene fusions in prostate cancer.
    Clark JP; Cooper CS
    Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct genomic aberrations associated with ERG rearranged prostate cancer.
    Demichelis F; Setlur SR; Beroukhim R; Perner S; Korbel JO; Lafargue CJ; Pflueger D; Pina C; Hofer MD; Sboner A; Svensson MA; Rickman DS; Urban A; Snyder M; Meyerson M; Lee C; Gerstein MB; Kuefer R; Rubin MA
    Genes Chromosomes Cancer; 2009 Apr; 48(4):366-80. PubMed ID: 19156837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.
    Kluth M; Galal R; Krohn A; Weischenfeldt J; Tsourlakis C; Paustian L; Ahrary R; Ahmed M; Scherzai S; Meyer A; Sirma H; Korbel J; Sauter G; Schlomm T; Simon R; Minner S
    Int J Oncol; 2015 Apr; 46(4):1637-42. PubMed ID: 25625310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERG gene rearrangements are common in prostatic small cell carcinomas.
    Lotan TL; Gupta NS; Wang W; Toubaji A; Haffner MC; Chaux A; Hicks JL; Meeker AK; Bieberich CJ; De Marzo AM; Epstein JI; Netto GJ
    Mod Pathol; 2011 Jun; 24(6):820-8. PubMed ID: 21336263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity.
    Cao Q; Yang S; Lv Q; Liu Y; Li L; Wu X; Qu G; He X; Zhang X; Sun S; Li B; An J; Hu T; Xue J
    Aging (Albany NY); 2018 Jun; 10(6):1390-1401. PubMed ID: 29915163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.